(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.16%) $0.928
(0.14%) $10.86
(-0.03%) $0.792
(-0.11%) $92.47
Live Chart Being Loaded With Signals
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases...
Stats | |
---|---|
Today's Volume | 1.91M |
Average Volume | 954 093 |
Market Cap | 6.57B |
EPS | $0 ( 2024-02-22 ) |
Next earnings date | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -66.29 |
ATR14 | $1.830 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-26 | Desai Antal Rohit | Sell | 134 | Class A common stock |
2023-09-26 | Desai Antal Rohit | Sell | 993 929 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 280 | Class A common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 278 309 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 699 | Stock Option (right to buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 4 695 639 |
Volume Correlation
Reata Pharmaceuticals Inc Correlation
10 Most Positive Correlations | |
---|---|
CREX | 0.957 |
MYRG | 0.875 |
ALLR | 0.869 |
MSSA | 0.849 |
SGEN | 0.847 |
NETE | 0.835 |
PLYA | 0.832 |
MHUA | 0.831 |
USAP | 0.83 |
SGTX | 0.825 |
10 Most Negative Correlations | |
---|---|
RMGBU | -0.875 |
ENVI | -0.851 |
EJFA | -0.838 |
ONEM | -0.837 |
ESSA | -0.837 |
SVOK | -0.824 |
SAII | -0.819 |
FNCB | -0.818 |
BSBK | -0.816 |
PAIC | -0.814 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Reata Pharmaceuticals Inc Correlation - Currency/Commodity
Reata Pharmaceuticals Inc Financials
Annual | 2022 |
Revenue: | $2.22M |
Gross Profit: | $2.22M (100.00 %) |
EPS: | $-8.59 |
Q2 | 2023 |
Revenue: | $22.75M |
Gross Profit: | $21.90M (96.28 %) |
EPS: | $5.12 |
Q1 | 2023 |
Revenue: | $195 000 |
Gross Profit: | $195 000 (100.00 %) |
EPS: | $-3.00 |
Q4 | 2022 |
Revenue: | $914 000 |
Gross Profit: | $914 000 (100.00 %) |
EPS: | $-2.35 |
Financial Reports:
No articles found.
Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators